- Home
- Automated
- NDF A-Z listing
- Faricimab
F
Faricimab
Subsidy Information and Financing Scheme
MAF
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Faricimab
General information
Subsidy Information and Financing Scheme
[MAF] Faricimab (Vabysmo) Injection 6 mg/0.05 mL
Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration.
Treatment of adults with visual impairment due to diabetic macular oedema.
Legend
This section shows the following:
Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs
Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List
Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List
As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.
Legend list
Indicator | Legend |
|---|---|
SDL | Standard Drug List |
MAF | Medical Assistance Fund |
SVL | Subsidised Vaccine List |
MSHL | Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List |
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to:
diabetic macular oedema; and
neovascular (wet) age-related macular degeneration.
Funding status
[R] Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 March 2024.
[NR] MAF assistance does not apply to any formulations or strengths of aflibercept for treating diabetic macular oedema or neovascular age-related macular degeneration.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Vabysmo Injection 6 mg/0.05 mL |
|